| Literature DB >> 32580721 |
Manas Kotepui1, Kwuntida Uthaisar Kotepui2, Giovanni D Milanez3, Frederick R Masangkay3.
Abstract
BACKGROUND: Although mixed infection by two Plasmodium species has been recognized, mixed infection by three different Plasmodium species within one individual has not been clarified. This study sought to determine the pooled prevalence and proportion of triple mixed Plasmodium spp. infection compared with double mixed infection.Entities:
Keywords: Concurrent infection; Mixed infection; Plasmodium; Quadruple infection; Triple infection
Mesh:
Year: 2020 PMID: 32580721 PMCID: PMC7315477 DOI: 10.1186/s12936-020-03292-8
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Flow chart for the study selection
Characteristics of the included studies
| No. | Author, year | Study area | Participants | Age range | Age groups (n) | Blood storage for PCR | DNA extraction | Investigated gene | PCR method | Malaria positive by PCR | Mixed infection (dual infection) | Mixed infection (Triple infection) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Asua et al. [ | Uganda | Malaria positive (499) | 6 months to 10 years | Dried blood spots | Chelex extraction kits | 18S rRNA | Nested PCR | 474 | Pf/Pm (19) Pf/Po (14) Pf/Pv (3) Pm/Pv (1) Total = 37 | Pf/Pm/Po (1) | |
| 2. | Barber et al. [ | Malaysia (2009–2011) | Malaria positive (653) | (19 years, IQR 7–32 years) | Triple infection: < 5 (1), 10–14 (1), 30–34 (1), 80–84 (1) Dual infection: < 5 (1), 5–9 (2), 10–14 (5), 15–19 (3), 20–24 (2), 25–29 (2), 30–34 (4), 35–39 (3), 40–44 (5), 45–49 (2), 50–54 (2), 70–74 (2), 75–79 (1) | NA | NA | 18S rRNA | Nested PCR | 445 | Pv/Pk (36) Pf/Pk (6) Pm/Pk (1) Pf/Pm (1) Total = 44 | Pf/Pv/Pk (2) Pv/Pm/Pk (2) |
| 3. | Calderaro et al. [ | Italy (2000–2007) | Febrile patients (701) | NA | EDTA blood | High Pure Template Preparation kit (Roche Diagnostics, Mannheim, Germany) | 18S rRNA | Nested PCR | 159 | Pf/Po (3) Pf/Pm (1) Total = 4 | Pf/Pm/Po (2) | |
| 4. | Camargo-Ayala et al. [ | Colombia (2012–2015) | Febrile patients (671) | < 5, 5–18, 18–60, and > 60 years | Triple infection: < 5 (4), 5–18 (2), 18–60 (6), > 60 (2) Dual infection: < 5 (16), 5–18 (56), 18–60 (139), > 60 (15) | EDTA blood | Pure Link Genomic DNA mini kit (Invitrogen) | 18S rRNA | Nested PCR | 531 | Pv/Pm (190) Pf/Pv (25) Pf/Pm (10) Total = 225 | Pf/Pm/Pv (14) |
| 5. | Dhangadamajhi et al. [ | India (2008) | Febrile and asymptomatic (242) | 0–5 years, 6–15, and > 15 years | Triple infection: 0–5 (1), 6–15 (2), > 15 (2) Dual infection: 0–5 (7), 6–15 (32), > 15 (39) | EDTA blood | Phenol–Chloroform extraction | 18S rRNA | Nested PCR | 197 | Pf/Pv (15) Pf/Pm (54) Pv/Pm (10) Total = 79 | Pf/Pm/Pv (5) |
| 6. | Dormond et al. [ | Switzerland (2004–2008) | Malaria positive (89) | >16 years | EDTA blood | MagNA Pure LC DNA isolation kit (Roche, Basel, Switzerland) | 18S rRNA | Nested PCR | 89 | Pf/Po (3) Pf/Pm (2) Total = 5 | Pf/Pm/Po (1) | |
| 7. | Fuehrer et al. [ | Bangladesh: Chittagong Hill Tracts (2007–2008) Malaria Research Initiative Bandarban field site (2008–2009) | Febrile patients (379) | Any age | Dried blood spots | Modified Chelex-based technique, the InstaGene Whole Blood Kit (Bio-Rad Laboratories, Hercules, CA) | 18S rRNA | Nested PCR | 189 | Pf/Pv (21) Pf/Pm (2) Total = 23 | Pf/Pm/Pv (2) | |
| 8. | Gabrielli et al. [ | Congo (2014) | Residents (306) | 1 week to < 5 years | Dried blood spots | The commercial kit Dried Blood spot DNA isolation Kit (Norgen Biotek Corp, Ontario, Canada) | 18S rRNA | Nested PCR | 164 | Pf/Pm (13) Pf/Po (2) Pf/Pv (1) Total = 16 | Pf/Pm/Pv (1) | |
| 9. | Hopkins et al. [ | Uganda (2010–2011) | Residents (272) | 5–81 years: 5–10, 11–20, and ≥ 21 years | EDTA blood | Phenol–Chloroform extraction | 18S rRNA | Nested PCR and qPCR | 199 | Pf/Pm (38) Pf/Po (8) Total = 46 | Pf/Pm/Po (10) | |
| 10. | Jiang et al. [ | Myanmar (2008) | Malaria positive (146) | NA | Dried blood spots | Chelex extraction kits | 18S rRNA | Nested PCR | 146 | Pf/Pk (13) Pv/Pk (13) Pf/Pv (10) Total = 36 | Pf/Pv/Pk (2) | |
| 11. | Kasehagen et al. [ | Papua New Guinea (2001–2003) | Residents (16,209) | < 2, 2.0–3.9, 4.0–6.9, 7.0–9.9, 10.0–19.9, 20.0–39.9, and ≥ 40 years | EDTA blood | QIAamp 96 DNA Blood Kit (QIAGEN, Valencia, CA) | 18S rRNA | LDR-FMA | 658 | Pf/Pv (72) Pf/Pm (32) Pf/Po (13) Pv/Pm (17) Pv/Po (9) Pm/Po (4) Total = 147 | Pf/Pm/Pv (28) Pf/Pv/Po (5) Pf/Pm/Po (4) Pv/Pm/Po (4) Pf/Pv/Pm/Po (11) | |
| 12. | Krishna et al. [ | India (2015) | Doubtful microscopic (355) | ≤ 1, > 1–4, >4–8, > 8–14, and > 14 years | Dried blood spots | FavorPrep Genomic DNA Mini Kit (Favorgen Biotech Corp., Taiwan). | 18S rRNA | Nested PCR | 353 | Pf/Pv (59) Pf/Pm (3) Total = 62 | Pf/Pm/Pv (5) Pf/Pv/Po (1) Pf/Pv/Pm/Po (1) | |
| 13. | Lorenzetti et al. [ | Brazil (2003–2005) | Malaria positive (115) | 18–52 years | EDTA blood | Phenol–Chloroform extraction | 18S rRNA | Nested PCR | 115 | Pf/Pm (2) Pf/Pv (28) Total = 30 | Pf/Pm/Pv (1) | |
| 14. | Marques et al. [ | Mozambique (2001–2002) | Residents (308) | 1–82 years | EDTA blood | Phenol–Chloroform extraction | 18S rRNA | Nested PCR | 115 | Pf/Pm (70) Pf/Po (10) Total = 80 | Pf/Pm/Po (9) | |
| 15. | May et al. [ | Nigeria (1996–1997) | Residents (593) | Children in Abanla (1–11 years), Children in Ibadan (3–8 years), Children in health centres in Ibadan (0.8–11 years), Healthy adults (15–56 years) | EDTA blood | DNA-Easy Kit (Invitrogen, St. Louis, MO) | 18S rRNA | Nested PCR | 165 | Pf/Pm (41) Pf/Po (12) Total = 53 | Pf/Pm/Po (27) | |
| 16. | Mehlotra et al. [ | Papua New Guinea (1998–1999) | Residents (1848) | All groups < 1–85 years: 2–4, 5–9, ≥ 10 years | Triple infection: 2–4 (2), 5–9 (8), ≥ 10 (24) Dual infection: 2–4 (14), 5–9 (51), ≥ 10 (115) | EDTA blood | QIAamp 96 spin blood kits (QIAGEN, Valencia, CA) | 18S rRNA | Nested PCR | 541 | Pf/Pv (116) Pf/Pm (27) Pf/Po (11) Pv/Pm (21) Pv/Po (4) Pm/Po (3) Total = 182 | Pf/Pm/Pv (23) Pf/Pv/Po (9) Pf/Pm/Po (1) Pf/Pv/Pm/Po (3) |
| 17. | Mehlotra et al. [ | Papua New Guinea (1996) | Malaria positive (173) | 5–10 and > 11 years | Triple infection: 5–10 (1), > 11 (0) Dual infection: 5–10 (6), > 11 (9) | EDTA blood | QIAamp 96 or individual spin blood kits (QIAGEN, Valencia, CA) | 18S rRNA | Nested PCR | 163 | Pf/Pv (40) Pf/Pm (16) Pf/Po (4) Pv/Pm (3) Total = 63 | Pf/Pm/Pv (27) Pf/Pv/Po (8) Pf/Pm/Po (5) Pv/Pm/Po (1) Pf/Pv/Pm/Po (9) |
| 18. | Mueller et al. [ | Papua New Guinea (2005) | Residents (2527) | < 10 and ≥ 20 years | EDTA blood | QIAmp 96 DNA Blood kits (Qiagen, CA) | 18S rRNA | A semi-quantitative post-PCR, ligase detection reaction/fluorescent microsphere assay (LDR-FMA) | 1844 | Pf/Pv (363) Pf/Pm (136) Pf/Po (27) Pv/Pm (26) Pv/Po (7) Pm/Po (1) Total = 560 | Pf/Pm/Pv (99) Pf/Pv/Po (33) Pf/Pm/Po (8) Pv/Pm/Po (6) Pf/Pv/Pm/Po (17) | |
| 19. | Nino et al. [ | Colombia (2015–2016) | Febrile patients (1392) | NA | EDTA blood | Pure Link Genomic DNA mini kit (Invitrogen) | 18S rRNA | Nested PCR | 596 | Pf/Pv (111) Pv/Pm (340) Pf/Pm (29) Total = 480 | Pf/Pm/Pv (52) | |
| 20. | Pati et al. [ | India | Febrile patients (1589) | Severe malaria (15–65 years) | Dried blood spots | Chelex extraction kits | 18S rRNA | Nested PCR | 110 | Pf/Pv (11) Pf/Pm (4) Pv/Pm (3) Total = 18 | Pf/Pm/Pv (5) | |
| 21. | Perandin et al. [ | Italy | Febrile patients (122) | NA | EDTA blood | The High Pure PCR template preparation kit (Roche, Indianapolis, Ind.) | 18S rRNA | Nested PCR | 62 | Pf/Po (1) | Pf/Pm/Po (1) | |
| 22. | Peruzzi et al. [ | Italy (2005–2006) | Febrile patients (139) | 2–49 years | Triple infection: 19 years | EDTA blood | High Pure PCR Template Preparation Kit” (Roche) | 18S rRNA | Nested PCR | 36 | None | Pf/Pm/Po (1) |
| 23. | Pongvongsa et al. [ | Laos-Vietnam border (2010) | Residents (3059) Sample for PCR (135) | Triple infection (Pf/Pv/Pk): mean 6.43 years (7) Dual infection (Pk/Pv): mean 7.4 years (5) | Dried blood spots | QIAamp DNA micro kit (QIAGEN, Tokyo, Japan) | 18S rRNA | Nested PCR | 90 | Pf/Pv (15) Pf/Pm (2 Pv/Pk (5) Total = 22 | Pf/Pm/Pv (1) Pf/Pv/Pk (7) | |
| 24. | Putaporntip et al. [ | Thailand (2006–2007) | Febrile patients (1874) | 1–81 years | Dried blood spots | Qiagen DNA Mini Kit | 18S rRNA | Nested PCR | 1751 | Pf/Pv (200) Pf/Pm (6) Pf/Po (2) Pf/Pk (5) Pv/Pm (8) Pv/Po (4) Pv/Pk (4) Pm/Po (1) Total = 230 | Pf/Pm/Pv (4) Pf/Pv/Po (7) Pf/Pv/Pm/Po (1) | |
| 25. | Rubio et al. [ | Spain (1997–1998) | Febrile patients (168) | NA | EDTA blood | Modified Chelex-based technique, the InstaGene Whole Blood Kit (Bio-Rad Laboratories, Hercules, CA) | 18S rRNA | Nested PCR | 89 | Pf/Pm (4) Pf/Po (1) Pf/Pv (3) Total = 8 | Pf/Pm/Pv (1) | |
| 26. | Rubio et al. [ | Equatorial Guinea (1996) | Febrile patients (159) | < 6 years | Dried blood spots | 5% Chelext-100 Resin (Bio-Rad Laboratories, Hercules, CA) | 18S rRNA | Nested PCR | 126 | Pf/Pm (36) Pf/Po (3) Pf/Pv (2) Total = 41 | Pf/Pv/Po (3) | |
| 27. | Sitali et al. [ | Zambia (2012) | Residents (873) | < 6 years | Dried blood spots | Chelex extraction kits | 18S rRNA | Nested PCR | 474 | Pf/Pm (31) Pf/Po (10) Pf/Pv (1) Total = 42 | Pf/Pm/Po (6) Pf/Pm/Pv (1) | |
| 28. | Sluydts et al. [ | Cambodia (2012) | Residents (5793) | 2–5, 5–14, 15–39, and ≥ 40 years | Dried blood spots | Instagene® Matrix resin (Bio-Rad, Singapore) | 18S rRNA | Two-step Real-time PCR | 368 | Pf/Pv (56) Pf/Pm (5) Pf/Po (1) Pv/Pm (3) Pv/Po (11) Total = 76 | Pf/Pm/Pv (4) Pf/Pv/Po (1) Pf/Pv/Pm/Po (1) | |
| 29. | Steenkeste et al. [ | Cambodia (2001) | Residents (337) | NA | Dried blood spots | the Instagene resin (Bio-Rad, USA) | 18S rRNA | Nested PCR | 140 | Pf/Pv (52) Pf/Pm (15) Pf/Po (4) Total = 71 | Pf/Pv/Po (7) Pf/Pm/Pv (24) Pf/Pv/Pm/Po (8) | |
| 30. | Steenkeste et al. [ | Cambodia (2001) | Residents (134) | < 1– > 60 years: < 1, 1, 2, 3, 4, 5–9, 10–14, 15–19, 20–39, 40–60, and > 60 years | Dried blood spots | Instagene resin (Bio-Rad, Germany) a | 18S rRNA | Nested PCR | 102 | Pf/Pm (4) Pf/Po (2) Pf/Pv (18) Pv/Pm (3) Total = 27 | Pf/Pm/Pv (7) Pf/Pv/Po (3) Pf/Pv/Pm/Po (3) | |
| 31. | Subissi et al. [ | Uganda (2010) | Residents (509) | 1–5, 6–10, and > 20 years | Triple infection: 1–5 (5), 6–10 (5), > 20 (0) Dual infection: 1–5 (27), 6–10 (24), > 20 (2) | Dried blood spots | QIAamp mini kit (QIAGEN, Venlo, The Netherlands) | 18S rRNA | Nested PCR | 299 | Pf/Pm (39) Pf/Po (14) Total = 53 | Pf//Pm/Po (10) |
| 32. | Toma et al. [ | Laos (1997) | Residents (336) | < 11– > 50 years: 2–68 years in Phavang and 0–75 years in Sisomsouen | EDTA blood | GFX Genomic Blood DNA Purification Kit (Pharmacia Biotech). | 18S rRNA | Nested PCR | 117 | Pf/Pv (19) Pf/Pm (2) Pv/Pm (2) Pv/Po (1) Total = 24 | Pf/Pm/Pv (1) Pf/Pv/Po (1) Pf/Pv/Pm/Po (1) | |
| 33. | Woldearegai et al. [ | Gabon (2016) | Residents (834) | 1–96 years: 1–5, 6–10, 11–15, 16–20, 21–25, 26–30, 31–40, 41–50, 51–60, 61–70, 71–80, and 81–96 years | EDTA blood | QIAsymphony DSP DNA kit | 18S rRNA | Nested PCR | 618 | Pf/Pm (123) Pf/Po (43) Pm/Po (1) Total = 167 | Pf//Pm/Po (51) | |
| 34. | Zhou et al. [ | Thailand (1995–1996) | Residents (548) | NA | Thick smear | 30% Chelex-100 | 18S rRNA | Nested PCR | 114 | Pf/Pv (10) Pf/Pm (6) Pv/Pm (19) Pv/Po (1) Total = 36 | Pf/Pm/Pv (49) Pf/Pv/Po (2) Pv/Pm/Po (1) Pf/Pv/Pm/Po (7) | |
| 35. | Zhou et al. [ | China (2008–2012) | Febrile patients (562) | NA | Dried blood spots | QIAamp DNA Mini Kit (QIAGEN China (Shanghai) | 18S rRNA | Nested PCR | 384 | Pf/Pv (67) Pv/Po (2) Pf/Pk (2) Pf/Pm (2) Po/Pm (1) Total = 74 | Pf/Pv/Po (3) Pf/Pm/Pv (1) Pv/Pm/Po (1) Pf/Pv/Pm/Po (1) | |
| Total = 12,023 | 2 species = 3059 Pf/Pv = 1318 Pf/Po = 188 Pf/Pm = 775 Pf/Pk = 26 Pv/Pm = 645 Pv/Po = 39 Pv/Pk = 58 Pm/Po = 10 Pm/Pk = 1 | 3 species = 601 Pf/Pm/Pv = 355 Pf/Pv/Po = 83 Pf/Pm/Po = 137 Pf/Pv/Pk = 11 Pv/Pm/Po = 13 Pv/Pm/Pk = 2 4 species = 53 |
Pf refers to P. falciparum
Pv refers to P. vivax
Po refers to P. ovale
Pm refers to P. malariae
Pk refers to P. knowlesi
NA Not Assessed
Quality of the included studies
| No. | References | Selection | Compatibility | Exposure | Total score (7) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Is the case definition adequate? | Representativeness of the cases | Selection of controls | Definition of controls | Ascertainment of exposure | Same method of ascertainment for cases and controls | Non-response Rate | ||||
| 1. | Asua et al. [ | * | NA | * | * | * | * | 5 | ||
| 2 | Barber et al. [ | * | NA | * | * | * | * | 5 | ||
| 3. | Calderaro et al. [ | * | * | NA | * | * | * | * | 6 | |
| 4. | Camargo-Ayala et al. [ | * | * | NA | * | * | * | * | 6 | |
| 5. | Dhangadamajhi et al. [ | * | * | NA | * | * | * | * | 6 | |
| 6. | Dormond et al. [ | * | NA | * | * | * | * | 5 | ||
| 7. | Fuehrer et al. [ | * | * | NA | * | * | * | * | 6 | |
| 8. | Gabrielli et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 9. | Hopkins et al. [ | * | □ | □ | NA | * | * | * | * | 7 |
| 10. | Jiang et al. [ | * | NA | * | * | * | * | 5 | ||
| 11. | Kasehagen et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 12. | Krishna et al. [ | * | NA | * | * | * | * | 5 | ||
| 13. | Lorenzetti et al. [ | * | NA | * | * | * | * | 5 | ||
| 14. | Marques et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 15. | May et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 16. | Mehlotra et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 17. | Mehlotra et al. [ | * | NA | * | * | * | * | 5 | ||
| 18. | Mueller et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 19. | Nino et al. [ | * | * | NA | * | * | * | * | 6 | |
| 20. | Pati et al. [ | * | * | NA | * | * | * | * | 6 | |
| 21. | Perandin et al. [ | * | * | NA | * | * | * | * | 6 | |
| 22. | Peruzzi et al. [ | * | * | NA | * | * | * | * | 6 | |
| 23. | Pongvongsa et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 24. | Putaporntip et al. [ | * | * | NA | * | * | * | * | 6 | |
| 25. | Rubio et al. [ | * | * | NA | * | * | * | * | 6 | |
| 26. | Rubio et al. [ | * | * | NA | * | * | * | * | 6 | |
| 27. | Sitali et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 28. | Sluydts et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 29. | Steenkeste et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 30. | Steenkeste et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 31. | Subissi et al. [ | □ | * | * | NA | * | * | * | * | 7 |
| 32. | Toma et al. [ | □ | * | * | NA | * | * | * | * | 7 |
| 33. | Woldearegai et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 34. | Zhou et al. [ | * | * | * | NA | * | * | * | * | 7 |
| 35. | Zhou et al. [ | * | * | NA | * | * | * | * | 6 | |
Fig. 2Pooled prevalence of triple mixed infections by Plasmodium species
Fig. 3Pooled proportion of triple mixed infections by Plasmodium species compared with double mixed infections
Fig. 4Subgroup analysis of triple mixed infections by Plasmodium species between areas of the included studies
Fig. 5Subgroup analysis of triple mixed infections by Plasmodium species between residents and febrile groups
Fig. 6Subgroup analysis of triple mixed infections by Plasmodium species between the two blood collection methods
Fig. 7Subgroup analysis of triple mixed infections by Plasmodium species between the two age groups
Fig. 8Publication bias among the included studies as demonstrated by funnel plot analysis